Snowdon

Snowdon, Inc. was a biopharmaceutical company founded in 2007 that specialized in discovering and developing small-molecule therapeutics. The firm's primary focus was on creating treatments for pain, neurological disorders, and infectious diseases. Snowdon utilized a proprietary computational platform, E-Prospector, to accelerate the drug discovery process, aiming to lower the associated costs and risks.

The company was founded by Dr. William J. Welsh. It was established with funding from an equity investment by the Foundation Venture Capital Group (FVCG), along with grants from the New Jersey Commission on Science & Technology and the National Institutes of Health (NIH). The company had research projects for conditions such as neuropathic pain (SND-121), tuberculosis (SND-159), and toxoplasmosis (SND-226). In November 2010, Snowdon was awarded a three-year contract from the Department of Defense worth up to $8.2 million for the discovery of treatments against biowarfare pathogens. The company was headquartered in Princeton, New Jersey, and collaborated with centers at the University of Medicine and Dentistry of New Jersey (UMDNJ) for its research. According to PitchBook, the company went out of business on November 19, 2020.

Keywords: biopharmaceutical, drug discovery, small-molecule therapeutics, E-Prospector, computational drug design, neuropathic pain, infectious diseases, neurological disorders, toxicology, biowarfare pathogens, preclinical development, pharmacology, medicinal chemistry